Who are low-dose epinephrine and tranexamic acid's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-epinephrine-and-tranexamic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

low-dose epinephrine and tranexamic acid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

low-dose epinephrine and tranexamic acid (low-dose epinephrine and tranexamic acid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination hemostatic and vasopressor agent. Area: Trauma, Hemorrhage, Critical Care.

marketed Combination hemostatic and vasopressor agent Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid) Trauma, Hemorrhage, Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

low-dose epinephrine and tranexamic acid (low-dose epinephrine and tranexamic acid) — King Abdullah International Medical Research Center. Low-dose epinephrine stimulates adrenergic receptors to increase heart rate and blood pressure, while tranexamic acid inhibits fibrinolysis to reduce bleeding.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
low-dose epinephrine and tranexamic acid TARGET	low-dose epinephrine and tranexamic acid	King Abdullah International Medical Research Center	marketed	Combination hemostatic and vasopressor agent	Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination hemostatic and vasopressor agent class)

King Abdullah International Medical Research Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low-dose epinephrine and tranexamic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-epinephrine-and-tranexamic-acid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab